BioCryst Pharmaceuticals (BCRX) Competitors $8.72 -0.24 (-2.68%) Closing price 07/15/2025 04:00 PM EasternExtended Trading$8.74 +0.02 (+0.29%) As of 07/15/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock BCRX vs. RGEN, HALO, IONS, MDGL, ALKS, LGND, FOLD, CLDX, DVAX, and INVAShould you be buying BioCryst Pharmaceuticals stock or one of its competitors? The main competitors of BioCryst Pharmaceuticals include Repligen (RGEN), Halozyme Therapeutics (HALO), Ionis Pharmaceuticals (IONS), Madrigal Pharmaceuticals (MDGL), Alkermes (ALKS), Ligand Pharmaceuticals (LGND), Amicus Therapeutics (FOLD), Celldex Therapeutics (CLDX), Dynavax Technologies (DVAX), and Innoviva (INVA). These companies are all part of the "biotechnology" industry. BioCryst Pharmaceuticals vs. Its Competitors Repligen Halozyme Therapeutics Ionis Pharmaceuticals Madrigal Pharmaceuticals Alkermes Ligand Pharmaceuticals Amicus Therapeutics Celldex Therapeutics Dynavax Technologies Innoviva Repligen (NASDAQ:RGEN) and BioCryst Pharmaceuticals (NASDAQ:BCRX) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, profitability, institutional ownership, risk, earnings, dividends, media sentiment and analyst recommendations. Do analysts recommend RGEN or BCRX? Repligen currently has a consensus target price of $170.75, suggesting a potential upside of 44.58%. BioCryst Pharmaceuticals has a consensus target price of $16.70, suggesting a potential upside of 91.51%. Given BioCryst Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe BioCryst Pharmaceuticals is more favorable than Repligen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Repligen 0 Sell rating(s) 4 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.69BioCryst Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.90 Is RGEN or BCRX more profitable? Repligen has a net margin of -3.93% compared to BioCryst Pharmaceuticals' net margin of -10.62%. Repligen's return on equity of 4.53% beat BioCryst Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Repligen-3.93% 4.53% 3.17% BioCryst Pharmaceuticals -10.62%N/A -11.06% Do institutionals & insiders hold more shares of RGEN or BCRX? 97.6% of Repligen shares are owned by institutional investors. Comparatively, 85.9% of BioCryst Pharmaceuticals shares are owned by institutional investors. 1.2% of Repligen shares are owned by insiders. Comparatively, 4.8% of BioCryst Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has higher valuation and earnings, RGEN or BCRX? Repligen has higher revenue and earnings than BioCryst Pharmaceuticals. Repligen is trading at a lower price-to-earnings ratio than BioCryst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRepligen$634.44M10.46-$25.51M-$0.45-262.44BioCryst Pharmaceuticals$450.71M4.05-$88.88M-$0.26-33.54 Does the media favor RGEN or BCRX? In the previous week, Repligen had 5 more articles in the media than BioCryst Pharmaceuticals. MarketBeat recorded 9 mentions for Repligen and 4 mentions for BioCryst Pharmaceuticals. Repligen's average media sentiment score of 1.10 beat BioCryst Pharmaceuticals' score of 0.71 indicating that Repligen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Repligen 7 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BioCryst Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk & volatility, RGEN or BCRX? Repligen has a beta of 1.11, meaning that its stock price is 11% more volatile than the S&P 500. Comparatively, BioCryst Pharmaceuticals has a beta of 1.04, meaning that its stock price is 4% more volatile than the S&P 500. SummaryRepligen beats BioCryst Pharmaceuticals on 10 of the 15 factors compared between the two stocks. Get BioCryst Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for BCRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BCRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BCRX vs. The Competition Export to ExcelMetricBioCryst PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.87B$2.44B$5.61B$9.30BDividend YieldN/A1.79%4.23%4.03%P/E Ratio-33.549.1428.5219.58Price / Sales4.05679.35426.1793.37Price / CashN/A164.3436.0257.93Price / Book-3.794.608.135.54Net Income-$88.88M$30.99M$3.24B$257.73M7 Day Performance-3.75%-1.81%0.20%-0.08%1 Month Performance-15.26%5.73%5.98%8.09%1 Year Performance14.29%-7.03%26.15%13.02% BioCryst Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BCRXBioCryst Pharmaceuticals4.1873 of 5 stars$8.72-2.7%$16.70+91.5%+21.4%$1.87B$450.71M-33.54530RGENRepligen4.6899 of 5 stars$124.43-2.4%$172.83+38.9%-3.7%$6.99B$634.44M-276.511,778Positive NewsHALOHalozyme Therapeutics4.9624 of 5 stars$54.22+0.4%$61.90+14.2%+7.7%$6.68B$1.02B14.42390Positive NewsIONSIonis Pharmaceuticals4.5231 of 5 stars$41.78-2.8%$58.25+39.4%-11.7%$6.65B$705M-13.971,069MDGLMadrigal Pharmaceuticals4.314 of 5 stars$289.17-3.2%$420.63+45.5%+11.1%$6.42B$180.13M-16.0290Positive NewsALKSAlkermes4.8356 of 5 stars$29.23+1.3%$40.00+36.8%+23.4%$4.82B$1.56B13.991,800News CoveragePositive NewsUpcoming EarningsAnalyst ForecastLGNDLigand Pharmaceuticals4.0468 of 5 stars$113.76-0.7%$146.14+28.5%+28.6%$2.19B$167.13M-15.9880FOLDAmicus Therapeutics4.0822 of 5 stars$6.05-0.8%$16.22+168.1%-44.4%$1.86B$528.29M-67.21480CLDXCelldex Therapeutics2.4737 of 5 stars$20.94-4.8%$50.11+139.3%-42.2%$1.39B$7.56M-7.76150News CoveragePositive NewsDVAXDynavax Technologies4.4421 of 5 stars$10.30+0.3%$24.00+133.0%-1.1%$1.24B$277.25M-19.81350INVAInnoviva4.0532 of 5 stars$18.91-1.6%$55.00+190.9%+18.5%$1.19B$369.84M-18.72100News CoverageAnalyst ForecastAnalyst Revision Related Companies and Tools Related Companies RGEN Competitors HALO Competitors IONS Competitors MDGL Competitors ALKS Competitors LGND Competitors FOLD Competitors CLDX Competitors DVAX Competitors INVA Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BCRX) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhy Elon is funding the “Quantum Power Grid”Elon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioCryst Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioCryst Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
